间充质干细胞（MSC）是一类特征明确的成体干细胞，具有分化为脂肪细胞、软骨细胞、成骨细胞、肌腱细胞及肌肉细胞等多种间充质组织谱系的潜能。由于其发育可塑性和多向分化能力，MSC 在再生医学领域备受关注，可用于替代或修复受损组织。胎肝是早期造血细胞的来源，同时也被认为是多能干细胞的潜在来源。在无血清培养条件下加入转化生长因子（TGF），MSC 可分化为软骨细胞；而在含血清培养体系中加入抗坏血酸和地塞米松，则可促进其向成骨细胞分化。MSC 既具自我更新能力，也能分化为多种间充质组织细胞，因此可移植至损伤部位，或接种于仿生支架上构建功能性组织工程结构。
人肝脏间充质干细胞(HMSC-he) 由 ScienCell Research Laboratories 从人肝脏组织中分离获得，于第一代（P1）冻存并以冷冻形式提供。每瓶含细胞数大于 5 × 105 个，体积为 1 ml。HMSC-he 可通过 CD73 和/或 CD90 特异性抗体进行免疫荧光鉴定，脂肪诱导分化后经 Oil Red O 染色验证，成骨诱导分化后经 Alizarin Red 染色验证；检测结果显示对 HIV-1、HBV、HCV、支原体、细菌、酵母菌及真菌均为阴性。在 ScienCell Research Laboratories 提供的培养条件下，HMSC-he 可保证至少完成 15 次群体倍增。
推荐培养基
建议使用间充质干细胞培养基（MSCM，目录编号 #7501）进行 HMSC-he 的体外培养。
Product Sheets
7520
Search for a Certificate of Analysis by Lot Number below:
Hepatocellular carcinoma (HCC) remains a common and lethal cancer. Cancer stem cells, or tumor-initiating cells (TICs), are thought to contribute to the pathogenesis of H... More
Hepatocellular carcinoma (HCC) remains a common and lethal cancer. Cancer stem cells, or tumor-initiating cells (TICs), are thought to contribute to the pathogenesis of HCC, but remain to be fully characterized. Unbiased screens of primary human HCC cells for the identification of novel HCC TIC markers have not been reported. We conducted high-throughput flow cytometry (HT-FC) profiling to characterize the expression of 375 CD antigens on tumor cells from 10 different human HCC samples. We selected 91 of these for further analysis based on HT-FC data that showed consistent expression in discrete, rare, sortable populations of HCC cells. Nine of these CD antigens demonstrated significantly increased expression in the EpCAM+ stem/progenitor fraction of a human HCC cell line and were further evaluated in primary human HCC tissues from 30 different patients. Of the nine tested, only CD146 demonstrated significantly increased expression in HCC tumor tissue as compared with matched adjacent non-tumor liver tissue. CD146+CD31−CD45− cells purified from HCC tumors and cell lines demonstrated a unique phenotype distinct from mesenchymal stem cells. As compared with other tumor cell fractions, CD146+CD31−CD45− cells showed significantly increased colony-forming capacity in vitro, consistent with TICs. This study demonstrates that HT-FC screening can be successfully applied to primary human HCC and reveals CD146 to be a novel TIC marker in this disease. Less
ScienCell Research Laboratories (SRL) takes pride in being a resource for researchers all over the world. The publications listed here are not meant as an endorsement or confirmation of the reliability of the products.
